Literature DB >> 17430492

Successful cardiac transplantation in Barth syndrome--single-centre experience of four patients.

Jasveer Mangat1, Tracy Lunnon-Wood, Philip Rees, Martin Elliott, Michael Burch.   

Abstract

We describe four patients with Barth syndrome who have undergone successful orthotopic heart transplantation. Patients are one, seven, 12.5 and 14.7 yr post-transplantation. One episode of severe infection occurred. Renal dysfunction and coronary allograft vasculopathy do not appear accelerated over non-Barth patients. Despite withholding purine synthesis inhibitors, these patients have not demonstrated an increased rate of rejection.

Entities:  

Mesh:

Year:  2007        PMID: 17430492     DOI: 10.1111/j.1399-3046.2006.00629.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  18 in total

Review 1.  Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review.

Authors:  Ting-Yu Yen; Wuh-Liang Hwu; Yin-Hsiu Chien; Mei-Hwan Wu; Ming-Tai Lin; Lon-Yen Tsao; Wu-Shiun Hsieh; Ni-Chung Lee
Journal:  Eur J Pediatr       Date:  2007-09-11       Impact factor: 3.183

Review 2.  Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.

Authors:  Hana M Zegallai; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2021-01-07       Impact factor: 3.396

3.  Left ventricular noncompaction cardiomyopathy in Barth syndrome: an example of an undulating cardiac phenotype necessitating mechanical circulatory support as a bridge to transplantation.

Authors:  Samuel P Hanke; Aimee B Gardner; John P Lombardi; Peter B Manning; David P Nelson; Jeffrey A Towbin; John L Jefferies; Angela Lorts
Journal:  Pediatr Cardiol       Date:  2012-03-17       Impact factor: 1.655

Review 4.  Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.

Authors:  F Lamari; F Mochel; F Sedel; J M Saudubray
Journal:  J Inherit Metab Dis       Date:  2012-07-20       Impact factor: 4.982

Review 5.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

Review 6.  How can we treat mitochondrial encephalomyopathies? Approaches to therapy.

Authors:  Rita Horvath; Grainne Gorman; Patrick F Chinnery
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

7.  Natural history of Barth syndrome: a national cohort study of 22 patients.

Authors:  Charlotte Rigaud; Anne-Sophie Lebre; Renaud Touraine; Blandine Beaupain; Chris Ottolenghi; Allel Chabli; Helene Ansquer; Hulya Ozsahin; Sylvie Di Filippo; Pascale De Lonlay; Betina Borm; Francois Rivier; Marie-Catherine Vaillant; Michèle Mathieu-Dramard; Alice Goldenberg; Géraldine Viot; Philippe Charron; Marlene Rio; Damien Bonnet; Jean Donadieu
Journal:  Orphanet J Rare Dis       Date:  2013-05-08       Impact factor: 4.123

8.  Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth.

Authors:  C G Steward; R A Newbury-Ecob; R Hastings; S F Smithson; B Tsai-Goodman; O W Quarrell; W Kulik; R Wanders; M Pennock; M Williams; J L Cresswell; I L Gonzalez; P Brennan
Journal:  Prenat Diagn       Date:  2010-10       Impact factor: 3.050

Review 9.  The 3-methylglutaconic acidurias: what's new?

Authors:  Saskia B Wortmann; Leo A Kluijtmans; Udo F H Engelke; Ron A Wevers; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2010-09-30       Impact factor: 4.982

Review 10.  Barth syndrome.

Authors:  Sarah L N Clarke; Ann Bowron; Iris L Gonzalez; Sarah J Groves; Ruth Newbury-Ecob; Nicol Clayton; Robin P Martin; Beverly Tsai-Goodman; Vanessa Garratt; Michael Ashworth; Valerie M Bowen; Katherine R McCurdy; Michaela K Damin; Carolyn T Spencer; Matthew J Toth; Richard I Kelley; Colin G Steward
Journal:  Orphanet J Rare Dis       Date:  2013-02-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.